Lupin Q1 FY24 Growth Metrics and ESG Goals
India: Bouncing Back
India Prescription business has grown >13% ex
Cidmus and NLEM impact in Q1 FY24
India Sales (INR mn)
15,841
14,920
15,213
16,384
14,786
Q1 FY23
Q2FY23
Q3FY23
Q4FY23
Q1FY24
•
Cardiac and Respiratory are back on growth trajectory
Al, Respiratory and Gynaecology reported double-digit
growth in Q1 FY24
.
•
LUPIN
Leveraging therapy leadership by adding 6
new divisions
#2 rank
Respiratory
#3 rank
#3 rank
Diabetes Care
Cardiac
~7,000 Total MEs¹ and ~9,100 total sales force
Launched "Uday" division to cater to extra Urban
Continued launch momentum with 4 new introductions
in the quarter
New Introductions
Three therapies - Cardiac, Anti Diabetes and
Respiratory are above INR 10 bn in sales
1 in
Diabetes Care
1 in
Cardiac
J2 in
respiratory
Lupin grew at par with the market at 8.5% in Q1, ex-
inlicensed portfolio
Poised to launch >21 products in FY24
6View entire presentation